Recent discussions on X about BioXcel Therapeutics (BTAI) have centered around the company’s latest clinical advancements, particularly the completion of the Phase 3 SERENITY At-Home trial for BXCL501, a treatment for acute agitation. Posts on the platform highlight a significant surge in stock price, with some noting an increase of over 85% following the trial news. The anticipation of topline data expected in Q3 2025 has sparked considerable interest among investors.
Additionally, there’s buzz about BioXcel’s plans to submit a Supplemental New Drug Application by year-end, which many see as a critical step forward. Some discussions also touch on the company’s broader neuroscience pipeline, with users expressing optimism about future growth despite ongoing net losses. The tone on X reflects a mix of excitement and cautious hope as the market awaits further developments.
Note: This discussion summary was generated from an AI condensation of post data.
BioXcel Therapeutics Hedge Fund Activity
We have seen 1 institutional investors add shares of BioXcel Therapeutics stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 4,315,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $8,759,450
- UBS GROUP AG removed 1,276,893 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,592,092
- VANGUARD GROUP INC removed 1,187,466 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,410,555
- BLACKROCK, INC. removed 380,608 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $772,634
- GEODE CAPITAL MANAGEMENT, LLC removed 311,965 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $633,288
- WELLS FARGO & COMPANY/MN removed 199,010 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $403,990
- MILLENNIUM MANAGEMENT LLC removed 104,972 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $213,093
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BioXcel Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $BTAI in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- LUCID CAPITAL MARKETS issued a "Buy" rating on 07/15/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/23/2025
- Rodman & Renshaw issued a "Buy" rating on 03/19/2025
To track analyst ratings and price targets for BioXcel Therapeutics, check out Quiver Quantitative's $BTAI forecast page.
BioXcel Therapeutics Price Targets
Multiple analysts have issued price targets for $BTAI recently. We have seen 3 analysts offer price targets for $BTAI in the last 6 months, with a median target of $65.0.
Here are some recent targets:
- Elemer Piros from LUCID CAPITAL MARKETS set a target price of $66.0 on 07/15/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $8.0 on 06/23/2025
- Elemer Piros from Rodman & Renshaw set a target price of $65.0 on 03/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
